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Introduction: Mirtazapine is a noradrenergic and serotonergic anti-
depressant mainly acting through blockade of presynaptic alpha-2 
receptors. Published data on pregnancy outcome after exposure to 
mirtazapine are scarce. This study addresses the risk associated with 
exposure to mirtazapine during pregnancy.
Patients (or Materials) and Methods: Multicenter (n = 11), observa-
tional prospective cohort study comparing pregnancy outcomes after 
exposure to mirtazapine with 2 matched control groups: exposure 
to any selective serotonin reuptake inhibitor (SSRI) as a disease-
matched control group, and general controls with no exposure to 
medication known to be teratogenic or to any antidepressant. Data 
were collected by members of the European Network of Teratology 
Information Services (ENTIS) during individual risk counseling 
between 1995 and 2011. Standardized procedures for data collec-
tion were used in each center.
Results: A total of 357 pregnant women exposed to mirtazapine 
at any time during pregnancy were included in the study and com-
pared with 357 pregnancies from each control group. The rate of 
major birth defects between the mirtazapine and the SSRI group 
did not differ significantly (4.5% vs 4.2%; unadjusted odds ratio, 
1.1; 95% confidence interval, 0.5–2.3, P = 0.9). A trend toward a 
higher rate of birth defects in the mirtazapine group compared with 
general controls did not reach statistical significance (4.2% vs 1.9%; 
OR, 2.4; 95% CI, 0.9–6.3; P = 0.08). The crude rate of spontane-
ous abortions did not differ significantly between the mirtazapine, 
the SSRI, and the general control groups (9.5% vs 10.4% vs 8.4%; 
P = 0.67), neither did the rate of deliveries resulting in live births 
(79.6% vs 84.3% in both control groups; P = 0.15). However, a 
higher rate of elective pregnancy-termination was observed in the 
mirtazapine group compared with SSRI and general controls (7.8% 
vs 3.4% vs 5.6%; P = 0.03). Premature birth (< 37 weeks) (10.6% 
vs 10.1% vs 7.5%; P = 0.38), gestational age at birth (median, 39 
weeks; interquartile range (IQR), 38–40 in all groups; P = 0.29), 
and birth weight (median, 3320 g; IQR, 2979–3636 vs 3230 g; IQR, 
2910–3629 vs 3338 g; IQR, 2967–3650; P = 0.34) did not differ 
significantly between the groups.
Conclusion: This study did not observe a statistically significant 
difference in the rate of major birth defects between mirtazapine, 
SSRI-exposed, and nonexposed pregnancies. A slightly higher rate 
of birth defects was, however, observed in the mirtazapine and SSRI 
groups compared with the low rate of birth defects in our general 
controls. Overall, the pregnancy outcome after mirtazapine exposure 
in this study is very similar to that of the SSRI-exposed control group.
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Introduction: Spontaneous abortions are the most common com-
plication of pregnancy and nonsteroidal anti-inflammatory drugs 
(NSAID) are among the most widely used groups of drugs during the 
first trimester of pregnancy. Published data are inconsistent regarding 
the risk for spontaneous abortions after exposure to NSAID.
Patients (or Materials) and Methods: A population-based retrospec-
tive cohort study was conducted including all women who conceived 
between January 2003 and December 2009 and admitted for birth 
or diagnosed with spontaneous abortion at Soroka Medical Center, 
Clalit Health Services, Israel. A computerized database of medica-
tion dispension was linked with 2 computerized databases contain-
ing information on births and spontaneous abortions. Time-varying 
COX regression models were constructed adjusting for mother’s age, 
diabetes mellitus, hypothyroidism, hypercoagulable or inflammatory 
conditions, history of recurrent miscarriages, presence of intrauterine 
contraceptive device, ethnicity, and self-reporting tobacco use during 
pregnancy and the year of pregnancy.
Results: There were 65,457 women who conceived during the study 
period and admitted at SMC: 58,949 (90.1%) for birth and 6508 
(9.9%) for spontaneous abortion. A total of 4495 (6.9%) pregnant 
women were exposed to NSAID during the study period. Exposure 
to NSAID was not an independent risk factor for spontaneous abor-
tion as groups (adjusted hazard ratio [HR], 1.08; 95% confidence 
interval [CI], 0.97–1.20 and adjusted HR, 1.67; 95% CI 0.95–2.95 
for nonselective and selective COX2 inhibitors, respectively) or as 
specific drugs. Additionally, no dose response effect was found.
Conclusion: In this large population-based retrospective cohort 
study, no increased risk for spontaneous abortions was found fol-
lowing exposure to NSAID Table. 
Table.  The unadjusted and adjusted risk (hazard ratios and 
95% CI) for spontaneous abortion following exposure 
to NSAID: results from time-varying multivariate Cox 
regression models.
Spontaneous abortions  
Hazard ratio (95% Ci)
unadjusted adjusted*
Nonselective COX inhibitors 1.13 (1.01–1.25) 1.08 (0.97–1.20)
Ibuprofen 1.13 (0.98–1.30) 1.05 (0.92–1.21)
Diclofenac 1.21 (0.98–1.48) 1.19 (0.97–1.47)
Indomethacin 3.54 (2.20–5.71) 3.33 (2.06–5.36)
Naproxen 1.87 (0.66–1.17) 0.88 (0.66–1.18)
Etodolac 1.26 (0.88 –1.80) 0.14 (0.8–1.64)
COX2 selective inhibitors 1.97 (1.12–3.47) 1.67 (0.95–2.95)
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Introduction: The pharmaceutical aspects of drug administration in 
clinical trials receive poor consideration compared with the impor-
tant attention devoted to the analytical and mathematical aspects 
